Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by equities research analysts at Royal Bank of Canada from a “sector perform” rating to an “outperform” rating in a research note issued on Monday, MarketBeat.com reports. The brokerage currently has a $137.00 price objective on the stock, down from their prior price objective of $138.00. […] - 2025-04-16 05:56:51
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price target reduced by UBS Group from $154.00 to $137.00 in a research report report published on Friday,Benzinga reports. They currently have a buy rating on the stock. A number of other analysts have also weighed in on NBIX. Royal Bank of Canada cut their target price […] - 2025-04-07 05:38:48
Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) have received an average recommendation of “Moderate Buy” from the twenty-three analysts that are currently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation, seventeen have given a buy recommendation and one has issued a strong buy recommendation on […] - 2025-04-03 06:06:54
American Century Companies Inc. decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 49.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 92,523 shares of the company’s stock after selling 88,727 shares during the period. American Century Companies […] - 2025-04-02 07:54:55
Corient Private Wealth LLC grew its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 64.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,927 shares of the company’s stock after purchasing an additional 3,094 shares during the quarter. Corient Private […] - 2025-03-27 09:14:52
Envestnet Portfolio Solutions Inc. boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 10.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,868 shares of the company’s stock after acquiring an additional 278 shares […] - 2025-03-27 09:14:51
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price target hoisted by JPMorgan Chase & Co. from $183.00 to $184.00 in a report published on Wednesday,Benzinga reports. The brokerage currently has an overweight rating on the stock. Several other research analysts also recently commented on NBIX. Barclays increased their price objective on Neurocrine Biosciences from […] - 2025-03-27 07:47:06
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Wednesday. A number of other analysts have also recently issued reports on NBIX. Deutsche Bank Aktiengesellschaft began coverage on shares of Neurocrine Biosciences […] - 2025-03-14 06:12:43
M&T Bank Corp lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 23.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,978 shares of the company’s stock after buying an additional 1,322 shares during the quarter. […] - 2025-03-12 08:19:05
Victory Capital Management Inc. decreased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 7.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 189,896 shares of the company’s stock after selling 14,309 shares during the period. Victory Capital Management […] - 2025-03-11 08:16:52
Charles Schwab Investment Management Inc. raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 762,557 shares of the company’s stock after buying an additional 15,266 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Neurocrine Biosciences were worth $104,089,000 as […] - 2025-03-10 11:50:03
Smartleaf Asset Management LLC lifted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 37.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 538 shares of the company’s stock after purchasing an additional 146 shares during the quarter. Smartleaf Asset Management LLC’s holdings in Neurocrine Biosciences were worth $74,000 as of its […] - 2025-03-10 09:10:55
IFP Advisors Inc raised its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 7.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,020 shares of the company’s stock after purchasing an additional 137 shares during the period. IFP Advisors Inc’s holdings […] - 2025-03-03 09:35:15
First Horizon Advisors Inc. decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 14.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 865 shares of the company’s stock after selling 142 shares during the period. First Horizon Advisors Inc.’s holdings in Neurocrine Biosciences were worth $118,000 at the end […] - 2025-02-27 09:05:01
Vontobel Holding Ltd. reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 42.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,442 shares of the company’s stock after selling 6,148 shares during the period. Vontobel Holding […] - 2025-02-19 09:15:16
Deutsche Bank Aktiengesellschaft initiated coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a report published on Tuesday, MarketBeat reports. The brokerage issued a hold rating and a $138.00 target price on the stock. NBIX has been the subject of a number of other research reports. Needham & Company LLC restated a “hold” […] - 2025-02-14 09:04:49
State of Alaska Department of Revenue cut its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 11,535 shares of the company’s stock after selling 200 shares during the quarter. State of Alaska Department […] - 2025-02-12 10:44:45
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty-three research firms that are currently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation, seventeen have issued a buy recommendation and one has issued a strong buy recommendation on […] - 2025-02-12 08:12:57
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective reduced by Guggenheim from $165.00 to $163.00 in a report published on Monday,Benzinga reports. They currently have a buy rating on the stock. NBIX has been the subject of several other research reports. Royal Bank of Canada decreased their price target on Neurocrine Biosciences from […] - 2025-02-11 07:12:48
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report)’s share price traded down 4.9% on Monday after Guggenheim lowered their price target on the stock from $165.00 to $163.00. Guggenheim currently has a buy rating on the stock. Neurocrine Biosciences traded as low as $116.48 and last traded at $116.60. 1,568,535 shares changed hands during mid-day […] - 2025-02-11 06:10:42
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price lowered by Royal Bank of Canada from $154.00 to $148.00 in a report released on Friday,Benzinga reports. The brokerage currently has a sector perform rating on the stock. A number of other research firms have also recently weighed in on NBIX. Canaccord Genuity Group lowered […] - 2025-02-10 16:58:49
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective trimmed by Canaccord Genuity Group from $172.00 to $163.00 in a research note published on Friday,Benzinga reports. The firm currently has a buy rating on the stock. Other analysts have also recently issued research reports about the stock. Raymond James restated an “outperform” rating and […] - 2025-02-10 16:58:47
abrdn plc boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 14.8% during the fourth quarter, Holdings Channel reports. The firm owned 156,574 shares of the company’s stock after buying an additional 20,150 shares during the quarter. abrdn plc’s holdings in Neurocrine Biosciences were worth $21,372,000 at the end of […] - 2025-02-07 09:28:53
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $76.4 million dollar outflow -- that's a 1.2% decrease week over week ( - 2025-02-05 16:06:35
Tokio Marine Asset Management Co. Ltd. cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,183 shares of the company’s stock after selling 119 shares […] - 2025-02-05 10:54:50
Robeco Institutional Asset Management B.V. decreased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 96.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 14,634 shares of the company’s stock after selling 372,648 shares during the period. Robeco Institutional Asset Management […] - 2025-02-04 08:47:05
KBC Group NV lowered its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 24.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 14,330 shares of the company’s stock after selling 4,642 shares during the period. KBC Group NV’s holdings in Neurocrine Biosciences were […] - 2025-02-02 11:40:51
NBIX institutional holdings
The following institutional investment holdings of NBIX have been identified
Date
ETF ISIN/Name
Num Shares
Book value
Fatal error: Uncaught mysqli_sql_exception: Column 'Currency_Code' in field list is ambiguous in /var/www/liquidata/show_aggregate_holdings.php:119
Stack trace:
#0 /var/www/liquidata/show_aggregate_holdings.php(119): mysqli->query()
#1 {main}
thrown in /var/www/liquidata/show_aggregate_holdings.php on line 119